IA
RXRX icon

Integrity Alliance’s Recursion Pharmaceuticals RXRX Stock Holding History

Integrity Alliance’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35K Buy
+11,400
New +$44.1K ﹤0.01% 744

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Integrity Alliance's RXRX Position: Q1 2026 in Review

Integrity Alliance opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 11,400 shares worth $35K. The stake represents ﹤0.01% of the portfolio and ranks #744 among its holdings.

334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Integrity Alliance held 11,400 shares of Recursion Pharmaceuticals worth $35K as of Q1 2026.
  • Recursion Pharmaceuticals was a new Integrity Alliance position in Q1 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Integrity Alliance's portfolio in Q1 2026, its #744 holding.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Integrity Alliance's 13F filing for Q1 2026, filed 11 May 2026.